We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
Kura's Komzifti revenues rose 57% sequentially to $9.1 million in second-quarter 2026
KURA expects multiple 2026 data readouts, while $519 million in cash supports pipeline execution.
Ziftomenib data show strong AML activity, supporting its potential expansion into earlier treatment lines.
Shares of Kura Oncology (KURA - Free Report) have gained 37.6% over the past month compared with the industry’s 9.1% growth, driven primarily by improving investor confidence in its lead product, Komzifti’s (ziftomenib) commercial performance and positive pipeline developments.
Image Source: Zacks Investment Research
Komzifti Commercial Momentum Drives KURA’s Growth
Komzifti delivered strong momentum in its second full quarter following its commercial launch in 2025. It is an FDA-approved menin inhibitor for the treatment of patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The therapy is demonstrating rapid market adoption. In the second quarter of 2026, net product revenues reached $9.1 million, up 57% sequentially, while new patient starts increased 35% compared with the first quarter of 2026. The company witnessed a 59% sequential increase in prescription volume. This rapid uptake provides investors with greater confidence in the product’s ability to generate sustained revenue growth and potentially establish a leadership position across the AML treatment landscape.
Ziftomenib Has Significant Expansion Potential in AML
Investor sentiment has also improved as Kura is pursuing ziftomenib across a much broader AML treatment landscape. Long-term data from the early-stage KOMET-007 study showed strong activity with ziftomenib plus intensive chemotherapy, including 96% and 90% composite complete remission (CRc) rates in NPM1-mutated and KMT2A-rearranged AML, respectively, while combination data with venetoclax and azacitidine demonstrated an 87% overall response rate and 70% CRc rate in venetoclax-naïve patients. These results increase confidence in the ongoing KOMET-017 frontline registrational program and support the potential for ziftomenib to move beyond its current indication into earlier lines of AML treatment.
KURA’s Multiple Near-Term Pipeline Catalysts
Kura has several value-creating catalysts ahead. The company expects additional ziftomenib data from the KOMET-007, KOMET-008 and KOMET-001 studies during the second half of 2026, including frontline combinations and activity in additional genetically defined AML populations. The ongoing phase III KOMET-017 program is particularly important because successful development could expand ziftomenib into frontline AML and materially increase its addressable market.
Darlifarnib Provides a Second Pipeline Growth Opportunity
KURA’s pipeline is not solely dependent on ziftomenib. Darlifarnib, its farnesyl-transferase inhibitor, is being evaluated in solid tumors. Early clinical data showed encouraging activity when combined with targeted therapies, including adagrasib in KRAS G12C-mutated tumors and cabozantinib in clear-cell renal cell carcinoma. These findings support darlifarnib’s potential as a precision-combination platform across multiple targeted therapies and tumor types.
Kura’s Financial Position Supports Pipeline Execution
Kura ended the second quarter of 2026 with $519.0 million in cash, cash equivalents and short-term investments, supplemented by $180 million in anticipated collaboration payments from Kyowa Kirin. Management expects these resources to fund the ziftomenib AML program through topline results from the KOMET-017 study, anticipated in 2028.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 65.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 15.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.5% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Key Takeaways
Shares of Kura Oncology (KURA - Free Report) have gained 37.6% over the past month compared with the industry’s 9.1% growth, driven primarily by improving investor confidence in its lead product, Komzifti’s (ziftomenib) commercial performance and positive pipeline developments.
Image Source: Zacks Investment Research
Komzifti Commercial Momentum Drives KURA’s Growth
Komzifti delivered strong momentum in its second full quarter following its commercial launch in 2025. It is an FDA-approved menin inhibitor for the treatment of patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The therapy is demonstrating rapid market adoption. In the second quarter of 2026, net product revenues reached $9.1 million, up 57% sequentially, while new patient starts increased 35% compared with the first quarter of 2026. The company witnessed a 59% sequential increase in prescription volume. This rapid uptake provides investors with greater confidence in the product’s ability to generate sustained revenue growth and potentially establish a leadership position across the AML treatment landscape.
Ziftomenib Has Significant Expansion Potential in AML
Investor sentiment has also improved as Kura is pursuing ziftomenib across a much broader AML treatment landscape. Long-term data from the early-stage KOMET-007 study showed strong activity with ziftomenib plus intensive chemotherapy, including 96% and 90% composite complete remission (CRc) rates in NPM1-mutated and KMT2A-rearranged AML, respectively, while combination data with venetoclax and azacitidine demonstrated an 87% overall response rate and 70% CRc rate in venetoclax-naïve patients. These results increase confidence in the ongoing KOMET-017 frontline registrational program and support the potential for ziftomenib to move beyond its current indication into earlier lines of AML treatment.
KURA’s Multiple Near-Term Pipeline Catalysts
Kura has several value-creating catalysts ahead. The company expects additional ziftomenib data from the KOMET-007, KOMET-008 and KOMET-001 studies during the second half of 2026, including frontline combinations and activity in additional genetically defined AML populations. The ongoing phase III KOMET-017 program is particularly important because successful development could expand ziftomenib into frontline AML and materially increase its addressable market.
Darlifarnib Provides a Second Pipeline Growth Opportunity
KURA’s pipeline is not solely dependent on ziftomenib. Darlifarnib, its farnesyl-transferase inhibitor, is being evaluated in solid tumors. Early clinical data showed encouraging activity when combined with targeted therapies, including adagrasib in KRAS G12C-mutated tumors and cabozantinib in clear-cell renal cell carcinoma. These findings support darlifarnib’s potential as a precision-combination platform across multiple targeted therapies and tumor types.
Kura’s Financial Position Supports Pipeline Execution
Kura ended the second quarter of 2026 with $519.0 million in cash, cash equivalents and short-term investments, supplemented by $180 million in anticipated collaboration payments from Kyowa Kirin. Management expects these resources to fund the ziftomenib AML program through topline results from the KOMET-017 study, anticipated in 2028.
KURA’s Zacks Rank & Other Stocks to Consider
Kura currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 65.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 15.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.5% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.